The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Merck; Pfizer
Speakers' Bureau - Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); EA Pharma (Inst); Eisai (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Philippe Merle
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; EISAI; Ipsen; Lilly; Merck; Roche
Consulting or Advisory Role - Bayer Schering Pharma
 
Tim Meyer
Consulting or Advisory Role - Bayer; BeiGene; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Chugai Pharma; Eisai; Guardant Health; Lilly Japan; MSD; Novartis; Roche; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Ruocai Xu
No Relationships to Disclose
 
Julien Edeline
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Basilea; Bayer; BeiGene; Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Incyte; Ipsen; Merck Serono; MSD; Roche; SERVIER; Taiho Oncology
Research Funding - Beigene (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Exeliom Biosciences
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Zhenggang Ren
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Omega Therapeutics, Inc.; Ono Pharmaceutical; Roche
 
Peter R. Galle
Honoraria - Adaptimmune; AstraZeneca/MedImmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Guerbet; Ipsen; Lilly; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Shuichi Kaneko
Consulting or Advisory Role - Bayer; Eisai; Lilly
Research Funding - AVI Pharma; Bayer; Eisai; Lilly; Otsuka; Pfizer; Sumitomo Dainippon Pharma
Other Relationship - AVI Pharma; Bayer; Eisai; Lilly; Sumitomo Dainippon Pharma
 
Hiromitsu Kumada
Honoraria - Abbvie; Eisai; Sumitomo Pharma Oncology
 
Anran Wang
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Kalgi Mody
Employment - Eisai
Travel, Accommodations, Expenses - Eisai
 
Leonid Dubrovsky
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Abby B. Siegel
Employment - Merck
Stock and Other Ownership Interests - Merck
Patents, Royalties, Other Intellectual Property - Merck & Co., Inc. I have a patent pending related to a drug combination at Merck. I received 1$ (token) for this)
Travel, Accommodations, Expenses - Merck
 
Josep M Llovet
Consulting or Advisory Role - Astrazeneca; Bayer; Bluejay; Boston Scientific; Bristol Myers Squibb; Captor Therapeutics Inc; Eisai; Exelixis; Genentech; Glycotest; Ipsen; Iylon; Lilly; Merck; Mina Alpha Ltd; Nucleix; Omega Therapeutics; Roche
Research Funding - Bayer (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Bayer